Short-Term Efficacy of Low-Dose Venetoclax Combined with CHG Priming Regimen in Patients with AML and High-Risk MDS Ineligible for Intensive Chemotherapy.
10.19746/j.cnki.issn.1009-2137.2025.03.006
- Author:
Yu-Ze YANG
1
;
Mei ZHOU
1
;
Ya-Ru XU
2
;
Wen-Yan XU
2
;
Jie SUN
3
;
Yuan-Yuan ZHU
3
;
Yuan LI
4
;
Zhen-Xing GUO
1
Author Information
1. School of Medicine, Tsinghua University, Beijing 100084, China.
2. Department of Hematology/Oncology, The First Hospital of Tsinghua University, Beijing 100016, China.
3. Department of Hematology, The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
4. Department of Hematology, Beijing Shijingshan Hospital, Beijing 100043, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
myelodysplastic syndrome;
venetoclax;
CHG priming regimen;
efficacy
- MeSH:
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Aged;
Male;
Female;
Sulfonamides/therapeutic use*;
Middle Aged;
Myelodysplastic Syndromes/drug therapy*;
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use*;
Aged, 80 and over;
Retrospective Studies;
Cytarabine/administration & dosage*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Homoharringtonine/therapeutic use*
- From:
Journal of Experimental Hematology
2025;33(3):660-665
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the short-term efficacy and safety of low-dose venetoclax combined with CHG (cytarabine+homoharringtonine+G-CSF) priming regimen in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy.
METHODS:The data of 14 patients with AML or high-risk MDS admitted to the department of hematology/oncology of the First Hospital of Tsinghua University and 2 cooperative institutions from July 2022 to August 2023 were retrospectively analyzed. All the patients were treated with low-dose venetoclax combined with CHG priming regimen and the early induction (one course) efficacy and adverse reactions were observed.
RESULTS:Among the 14 patients, 10 were males and 4 were females, with a median age of 69.5 (46-83) years. After 1 cycle of induction chemotherapy, the complete remission (CR) rate was 64.3% (9/14) and overall response rate (ORR) was 78.6% (11/14). Among the 10 patients with adverse prognosis according to cytogenetics and molecular genetics, the CR rate was 50.0% (5/10), and ORR was 70.0% (7/10). In 7 patients with TP53 mutation, the CR rate was 42.9% (3/7) and ORR was 71.4% (5/7). In the 6 patients with complex karyotype, CR rate was 33.3% (2/6) and ORR was 66.7% (4/6). While the CR rate and ORR of 8 non-complex karyotype patients were both 87.5% (7/8), and the difference in CR rate between patients with complex karyotype and non-complex karyotype was statistically significant ( P < 0.05). The adverse reactions of chemotherapy were tolerable, without early treatment-related deaths.
CONCLUSION:Low-dose venetoclax combined with CHG priming regimen can be used as an effective treatment for AML and high-risk MDS patients who are ineligible for intensive chemotherapy, and it is safe and worthy of clinical application.
